Mereo BioPharma (MREO) Common Equity (2017 - 2026)

Mereo BioPharma (MREO) has reported Common Equity for 10 consecutive years, with $34.1 million the latest figure, recorded in Q1 2026.

• Quarterly Common Equity fell 43.32% year-over-year to $34.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.1 million (down 43.32% YoY) and the FY2025 annual result came in at $40.9 million, down 32.89% from the prior year.
• Common Equity fell to $34.1 million in Q1 2026 per MREO's latest filing, from $40.9 million in the prior quarter.
• Over the last five years, Common Equity for MREO reached as high as $87.6 million in Q2 2022 and fell as low as -$72.5 million in Q3 2024.
• A 5-year average of $47.0 million and a median of $50.5 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity tumbled 232.59% — and 2025, when it jumped 164.24%.
• Year by year, Common Equity stood at $72.6 million in 2022, then sank by 30.36% to $50.5 million in 2023, then gained by 20.64% to $61.0 million in 2024, then slumped by 32.89% to $40.9 million in 2025, then decreased by 16.77% to $34.1 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $34.1 million, $40.9 million, and $46.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.